Industrial automation solution provider Emerson expands into life since business by acquiring Fluxa. Fluxa is into developing computing technology to quickly find new therapies by helping drug development and manufacturing organizations harness the power of collaboration and data across sites, functions and processes.
Fluxa says in its pages it uses advanced analytics, IoT, cloud, edge, and artificial intelligence (AI) solutions specifically to life sciences functions such as R&D, manufacturing, supply chain, sales, and marketing. Fluxa’s web based PKM software application manages product and process specifications throughout the drug development lifecycle.
Emerson to offer Combined solution of Fluxa’s PKM software and DeltaV control system and life sciences automation software to speed up the development of new drug therapies into production. It is like blending scientific innovative process into manufacturing operation technologies of industrial automation.
“The life sciences industry has grown rapidly, and speed to market has become increasingly important since the emergence of COVID-19,” said Mark Bulanda, Executive President of Emerson Automation Solutions. “Emerson’s automation solutions and market leadership, combined with Fluxa’s software, automates technology transfer in one step, giving bio-pharmaceutical companies unprecedented agility to get therapies safely to patients during this critical time.”